Evidence map›Paper›PMID 30925755›Full record

ReviewMolecules (Basel, Switzerland)2019

Challenges in Translating from Bench to Bed-Side: Pro-Angiogenic Peptides for Ischemia Treatment.

Karel Petrak, Ravi Vissapragada, Siyu Shi, Zain Siddiqui, Ka Kyung Kim, Biplab Sarkar, Vivek A Kumar

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Karel PetrakNangioTx Inc., Newark, NJ 07102, USA. petrak@nangiotx.com.
Ravi VissapragadaDepartment of Gastrointestinal Surgery, Flinders Medical Centre, 5042 Bedford Park, South Australia, Australia. ravi.vissapragada@gmail.com.ORCID 0000-0001-5372-7674
Siyu ShiDepartment of Medicine Stanford School of Medicine, Stanford, CA 94305, USA. syshi@stanford.edu.ORCID 0000-0001-9010-7431
Zain SiddiquiDepartment of Biomedical Engineering, Newark, NJ 07102, USA. zs67@njit.edu.
Ka Kyung KimDepartment of Biomedical Engineering, Newark, NJ 07102, USA. kk564@njit.edu.
Biplab SarkarDepartment of Biomedical Engineering, Newark, NJ 07102, USA. bsarkar@njit.edu.
Vivek A KumarDepartment of Biomedical Engineering, Newark, NJ 07102, USA. vak@njit.edu.ORCID 0000-0001-7536-9281
Flinders Medical Centre · AURutgers, The State University of New Jersey · USStanford Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe progress and obstacles in the development of novel peptide-hydrogel therapeutics for unmet medical needs in ischemia treatment, focusing on the development and translation of therapies specifically in peripheral artery disease (PAD). Ischemia is a potentially life-threatening complication in PAD, which affects a significant percentage of the elderly population. While studies on inducing angiogenesis to treat PAD were started two decades ago, early results from animal models as well as clinical trials have not yet been translated into clinical practice. We examine some of the challenges encountered during such translation. We further note the need for sustained angiogenic effect involving whole growth factor, gene therapy and synthetic growth factor strategies. Finally, we discuss the need for tissue depots for de novo formation of microvasculature. These scaffolds can act as templates for neovasculature development to improve circulation and healing at the preferred anatomical location.

Indexed as

Translational Research, BiomedicalAngiogenic ProteinsAnimalsDisease Models, AnimalDrug DiscoveryHumansIschemiaNeovascularization, PhysiologicAngiogenic Proteinsangiogenesisdevelopmentischemiapeptidetherapeutictranslation

Identifiers

PMID30925755
PMCPMC6479440
OpenAlexW2923918411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.